U. S. SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549

                                   FORM 10-QSB



[x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934. For the quarterly period ended SEPTEMBER 30, 1997.


[ ] Transition  report  pursuant to Section 13 or 15 (d) of the  Securities
Exchange Act of 1934.

For the transition period from ______________ to ________________


                  Commission File Number: 0-5367


                         D-LANZ DEVELOPMENT GROUP, INC.
         -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)


            DELAWARE                                  11-1717709
       -------------------------------------------------------------------
       (State or other jurisdiction                  (I.R.S.Employer
       incorporation or organization                Identification No.)


                   400 GROVE STREET GLEN ROCK, NEW JERSEY
                   -------------------------------------------
                    (Address of principal executive offices)


                                  201-457-1221
                           ---------------------------
                           (Issuer's telephone number)

                                (Not Applicable)
              ----------------------------------------------------
              (Former name, former address and former fiscal year,
                          if changed since last report)


     Check whether the issuer

     (1) filed all  reports required  to be filed by Section 13 or 15(d) of the
Exchange  Act  during the past 12 months (or for such shorter  period  that the
registrant was required to file such reports), and

     (2) has been subject to such filing requirements for the past 90 days. Yes
     [X] No [ ]

     State the number of shares  outstanding of each of the issuer's classes of
common equity as of the latest practicable date:

     10,000,000 common shares as of SEPTEMBER 30, 1997



     Transitional Small Business Disclosure Format Yes [  ]  No [X]


                                     PART I
                              FINANCIAL INFORMATION

     Item 1. Financial Statements

    The condensed financial statements for the periods ended September 30, 1997
 included herein have been prepared by American Bio Medica Corporation,
(the  "Company")  without  audit, pursuant to the rules and  regulations of the
Securities  and  Exchange  Commission (the  "Commission").  In the  opinion  of
management, the statements include all adjustments  necessary to present fairly
the  financial position of the Company as of July 31, 1997,  and the results of
operations  and cash flows for the three month  periods ended July 31, 1996 and
1997.

                                        2




<PAGE>


<TABLE>
<CAPTION>

                         D-LANZ DEVELOPMENT GROUP, INC.
                         (A Development Stage Company)
                                  BALANCE SHEET

                                  September 30,
                                December 31, 1997
                                     1996           Unaudited
                                   ---------        ---------


<S>                               <C>               <C>

 Current assets
  Cash                            $        0        $2,000

                                    --------        ------
  Current assets                           0         2,000

Other assets
  License rights                                   252,500
                                                   -------
  Total other asset                                252,500
                                    --------       -------
Total assets                      $        0      $254,500
                                    ========       =======

                     Liabilities and Stockholders' Equity

Current liabilities

  Commitments and contingencies     $      0      $      0

Capital stock
<CAPTION>
Preferred stock- authorized 50,000,000 shares $.001 par value each. At December
 31, 1996 and September 30, 1997, the number of shares outstandings was -0-

Common  stock-authorized 100,000,000  common  shares,  par value $.001 each, at
  December  31,  1996 and September  30,  1997,  the  shares  outstanding  were
  1,551,394 and 10,000,000         <C>               <C>
  respectively.                         1,551         10,000

   Additional paid in capital               0        246,051
   Retained earnings              (     1,551)      (  1,551)
                                  -----------      ---------
Total stockholders' equity                  0        254,500
                                  -----------      ---------
Total liabilities
 and stockholders' equity         $         0       $254,500
                                   ==========       ========
</TABLE>
                 See accompanying notes to financial statements.

                                       3



<PAGE>
<TABLE>
<CAPTION>


                      D-LANZ DEVELOPMENT GROUP, INC.
                         (A Development Stage Company)
                           STATEMENT OF OPERATIONS
<S>                       <C>                    <C>
                          For the nine           For the nine                  
                          months ended           months
ended
                          September 30,         September 30,
                            1996                   1997
                           Unaudited             Unaudited
                         -------------          ------------

Revenue                     $     0                $      0
Less cost of
 goods sold                       0                       0
                            --------              ---------
Gross profit                      0                       0

Operations:
  General
   administrative                 0                       0
  Depreciation and
   amortization                   0                       0
                             ------                --------
Total expenses                    0                       0

Income (loss) from
  operations                      0                       0


Net Profit (Loss)
 from operations          $       0               $       0
                          ==========               ========
 Net income (loss)
  per share                 $     0                   $   0
                            ======                   ======
Total number of
 shares outstanding      10,000,000              10,000,000
                         ==========              ==========
</TABLE>

                 See accompanying notes to financial statements.

                                       4



<PAGE>
<TABLE>
<CAPTION>


                         D-LANZ DEVELOPMENT GROUP, INC.
                         (A Development Stage Company)
                            STATEMENT OF CASH FLOWS
<S>                              <C>                  <C>

                                 For the nine         For the nine
                                 months ended          months ended
                                 September 30,         September 30,
                                     1996                  1997
                                  Unaudited              Unaudited
                                  ---------              ---------
CASH FLOWS FROM
 OPERATING ACTIVITIES
  Net profit (loss)               $       0             $        0
Amortization and
 depreciation                             0                      0
                                   ---------              --------
Adjustments to
 reconcile net
  income to net cash

TOTAL CASH FLOWS
FROM OPERATIONS                           0                      0

CASH FLOW FROM
FINANCING ACTIVITIES
  Sale of common shares                                      2,000
                                                           -------
TOTAL CASH FLOWS FROM
FINANCING ACTIVITIES                                         2,000


NET INCREASE (DECREASE) IN CASH           0                  2,000
CASH BALANCE  BEGINNING OF PERIOD         0                      0
                                    --------             ---------
CASH BALANCE END OF PERIOD         $      0            $     2,000
                                   ========             ==========
</TABLE>

                 See accompanying notes to financial statements.

                                       5


<PAGE>

<TABLE>
<CAPTION>

                        D-LANZ DEVELOPMENT GROUP, INC.
                         (A Development Stage Company
                       STATEMENT OF STOCKHOLDERS' EQUITY

                                            Additional
                 Common    Common Preferred   paid-in     Retained
                  Stock    Stock    Stock     capital     Earnings      Total
               ---------- ------- --------- ----------   ----------    --------
<S>            <C>          <C>    <C>       <C>           <C>          <C>

12-31-1991     1,551,394    $1,551                         $(1,551)     $    0
               =========     =====                          ======       =====
12-31-1992     1,551,394    $1,551                         $(1,551)     $    0
               =========     =====                          ======       =====
12-31-1993     1,551,394    $1,551                         $(1,551)     $    0
               =========     =====                          ======       =====
12-31-1994     1,551,394    $1,551                         $(1,551)     $    0
               =========     =====                          ======       =====
12-31-1995     1,551,394    $1,551                         $(1,551)     $    0
               =========     =====                          ======       =====
12-31-1996     1,551,394    $1,551                         $(1,551)     $    0


Unaudited
09-30-1997     2,000,000     2,000                                       2,000
09-30-1997     6,448,606     6,449            246,051                  252,500
               ---------  --------     --  ----------    ----------  ---------
09-30-1997    10,000,000    10,000     $0  $  246,051   $(   1,551)   $254,500
              ==========  ========     ==  ==========    ==========  =========
<FN>
(1) Sale of shares  pursuant to Regulation D at $.001 per share (2) Issuance of
shares for acquisition of License Rights valued at $.01 per share
</FN>
</TABLE>

                                       6



<PAGE>


                         D-LANZ DEVELOPMENT GROUP, INC.
                         (A Development Stage Company
                        STATEMENT OF STOCKHOLDERS' EQUITY
                    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1997

1. BASIS OF PRESENTATION

     The  accompanying  unaudited  financial  statements of D-Lanz Development
Group, Inc., (the "Company"), reflect all adjustments which are, in the opinion
of  management,  necessary  to a fair statement  of the  results of the interim
periods  presented. All such adjustments are of a normal recurring nature. The
financial statements  should be read in conjunction with the notes to financial
statements contained in the Company's  Annual Report on Form 10KSB for the year
ended December 31, 1996.

2. NET INCOME PER SHARE

     Primary earnings per share are based on the total average number of common
and dilutive common equivalent shares outstanding during each quarter.The total
number of shares for computing primary  earnings per share were  10,000,000 and
10,000,000 for the quarters ended September 30, 1996 and 1997,respectively

4. ACCOUNTING FOR INCOME TAXES

     The Company follows Statement of Financial Accounting Standards (SFAS) No.
109,  "Accounting  for Income  Taxes," which  requires  an asset and  liability
approach of accounting for income taxes.Deferred tax assets and liabilities are
computed  annually for  differences between  financial  statement basis and tax
basis  of  assets,   liabilities and  available  general  business  tax  credit
carry-forwards.  A valuation allowance is established  when necessary to reduce
deferred tax assets to the amount expected to be realized.

5. MARKETABLE SECURITIES

     The Company adopted Financial Accounting Standards Board ("FASB") Statement
No. 115,  "Accounting  for Certain  Investments in Debt and Equity  Securities",
which  requires  that  investments  in  equity   securities  that  have  readily
determinable  fair values and  investments  in debt  securities be classified in
three categories: held-to-maturity, trading and available-for-sale. Based on the
nature of the assets held by the Company and Management's  investment  strategy,
the Company's investments have been classified as available-for-sale. Management
determines  the  appropriate  classification  of debt  securities at the time of
purchase and reevaluates such designation as of each balance sheet date.

     Securities classified as  available-for-sale  are carried at estimated fair
value, as determined by quoted market prices,  with unrealized gains and losses,
net of tax,  reported in a separate  component of stockholders'  equity. At July
31, 1997,  the Company had no  investments  that were  classified  as trading or
held-to-maturity as defined by the Statement.

                                       8



<PAGE>


     The following is a summary of cash, cash equivalents and available-for-sale
securities by balance sheet classification at September 30, 1997:
<TABLE>
<CAPTION>

                                                                 Estimated
                                        Gross     Gross             Fair
                                      Unrealized Unrealized        Market
                               Cost     Gains     Losses           Value
                               ----     -----     ------           ------
<S>                            <C>      <C>        <C>             <C> 
Cash                     $     2,000    $-0-       $-0-       $     2,000

                          ----------    ----       ----         ---------
Total cash and cash
   equivalents           $     2,000    $-0-       $-0-        $    2,000
                          ==========     ===        ===         =========

</TABLE>

6. ACQUISITION OF LICENSE RIGHTS

On September 30, 1997,  the Company issued  6,448,606  shares of common stock to
purchase from Health Technologies International, Inc. ("Health Tech") the rights
to manufacture and market certain  patented  technologies.  The License has been
valued at the historic cash  purchase  price of $252,500 paid by Health Tech for
the manufacturing and marketing rights.

Health  Tech  entered  into an  agreement  on August 15,  1996 with  Scantek,  a
Delaware  corporation located in Mountain Lakes, New Jersey for the licensing of
certain patented technology to manufacture and market for the countries of Chile
and Singapore.  The patented technology consists of a temperature sensing device
and diagnostic direct reading, digital device to screen the breast for
 abnormalities, including cancer.

As a result of the  acquisition,  the Company has been granted a  nonassignable,
indivisible,  nontransferable exclusive right and license within the territories
of Chile and  Singapore  to  assemble,  use and sell the devices for a period of
ending with the expiration of the applicable patents in these countries.  If the
Company fails to achieve for a period of 12  consecutive  months the minimum net
sales of the  devices  with  respect to each  country,  Scantek may upon 30 days
written  notice and at its option either  terminate this agreement or delete the
country from the  Company's  territories.  Minimum net sales as defined is based
upon market  penetration.  The size of the market in each of the three countries
will be computed using official government census information from each country.
The  market is  defined  as the lesser of two pairs of the device for each women
between  the  ages  of 25 and 70 or  such  usage  as may be  recommended  by the
relevant  medical  association  or  government  agency  in each  country  in the
Territory. The percentage of market penetration by year is as follows:
<TABLE>
<CAPTION>

                                          Year Percentage of  Market Penetration
<S>                                       <C>                   <C>
                                          1997                  0%
                                          1998                  1%
                                          1999                  3%
                                          2000                  4%
                                          2001 and after        5%
</TABLE>

This schedule is based upon the scheduled  delivery of an  operational  assembly
line, part of which will be installed in Scantek's facility,  part of which will
be  install  in  the  Company's  facility.  In  the  event  that  completion  of
installation of the turnkey  manufacturing line is delayed beyond June 30, 1997,
then the above referenced  years will be adjusted to appropriate  calendar years
so as not to prejudice the Company's 365 day time period in which to achieve the
graduated market penetration.

As of  September  30,  1997,  Health  Tech has paid to  Scantek a  nonrefundable
License Fees aggregating $252,500.

The Company is  required to pay a royalty  equal to 15% of Net Sales of Licensed
Devices in the  Territories  during  each  contract  year during the term of the
agreement.  The royalty paid, will in no instance be less than $1.00 per unit or
a  guaranteed  minimum  royalty  payable as follows:  $80,000 for the year 1997;
$200,000  for the year 1998;  $300,000  for the year 1999 and  $400,000 for each
year thereafter.

Royalties  are due and payable each quarter  either for the actual amount due or
25% of the minimum royalty payable for the year. The Company is required to sell
to  Scantek  2,000,000  shares of common  stock,  representing  20% of the total
issued  and  outstanding  common  shares  of the  Company  as of the date of the
agreement  for the  aggregate  sum of  $2,000.  or  $.001  per  share.  Under no
circumstances  will Scantek's  common stock position be diluted to less than 15%
of the issued and  outstanding  common  stock of the  Company.  In the event the
Company will receive at nominal cost warrants to purchase  sufficient  shares of
common  stock to  maintain  its 20%  ownership,  such  warrants  will  allow the
purchase  of  shares at $2.25  per  share  for five  years  from the date of the
agreement.   The   Company  is   required  to  arrange  to  purchase  a  turnkey
manufacturing  line.  Upon completion of the line, that portion of the line that
manufactures  Sensors for the  licensed  devices  will be  installed at the same
location as  Scantek's  own  manufacturing  facility.  Scantek will operate that
portion  of the line and to the  extent  of the  lines  manufacturing  capacity,
deliver the Company's  requirements  for Sensors to the Company's plant location
F.O.B.  for cost plus 25%.  Scantek  will  maintain  a purchase  money  security
interest in the sensors delivered pursuant to this agreement.

During  each  contract  year,  the  Company is required to spend 5% of net sales
during the immediately preceding year on advertising and promotion.

Upon  termination  of this  agreement,  the  Company  agrees  that  neither  the
Company's  officers,  directors,  principals nor its shareholders  will during a
period of 5 years from the date of termination  manufacture  Sensors or purchase
Sensors  manufactured  by any entity  other than Scantek for use in the licensed
devices or any competing device or directly or indirectly  manage,  operation or
control  of or be  connected  as an  officer,  director,  shareholder,  partner,
consultant, owner, employee, agent, lender, donor, vendor, or otherwise, or have
any  financial  interest  in or aid  assist  anyone  else in the  conduct of any
competing  entity which offers similar devices for sale. The Company is required
to  maintain  product  liability  insurance  with  a  limit  of  not  less  than
$1,000,000.


                                       9



<PAGE>


Item 2. Management's Discussion and Analysis or Plan of Operation

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
                OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                for the nine months ended September 30, 1996 and 1997
                 -------------------------------------------------

     Except for the description of historical facts contained herein,  this Form
10Q-SB  contains  certain  forward  looking  statements  that involve  risks and
uncertainties as detailed herein and from time to time in the Company's  filings
with the Securities and Exchange  Commission and elsewhere.  Such statements are
based on  management's  current  expectations  and are  subject  to a number  of
factors and uncertainties  which could cause actual results to differ materially
from those described in the forward-looking  statements.  These factors include,
among others, the Company's  fluctuations in sales and operating results,  risks
associated  with  international  operations  and  regulatory,   competitive  and
contractual risks and product development.

     Results of  operations  for the nine  months  ended  September  30, 1997 as
compared to the nine months ended September 30, 1996.
-------------------------------------------------------------------------

     Revenues  were $0 for the nine months ended  September 30, 1997 as compared
to $0 for the nine months ended September 30, 1996.  Costs of goods sold for the
nine months ended September 30, 1997, were $0 as compared to $0 for the
nine  months  ended  September  30,  1996  representing  a cost  of  goods  sold
percentage of 0% for the nine months ended  September 30, 1997 as compared to 0%
for the nine months ended  September 30, 1996. The cost of goods sold percentage
during the first quarter of fiscal 1998 remains  approximately  consistent  with
the percentage during the first quarter of fiscal 1997.

    General and  administrative  costs for the nine months ended September 30, 
1997 were  $0,  an  increase of 0% over  expenses of $0  for the nine months  
ended September 30,  1996.

     Liquidity  and capital  resources  as of the end of the nine  months  ended
September 30, 1997.
------------------------------------------------------------------------------

     The Company's cash balance was $2,000 and working  capital was $2,000 as at
September 30, 1997.

     The Company's  primary  short-term needs for capital,  which are subject to
change,  are for  development  of its  manufacturing  to adequately  deliver new
products and an increase in inventory levels to fill large anticipated orders.

                                       10



<PAGE>


     Income  tax:  As of  September  30,  1997,  the  Company  has  a  tax  loss
carry-forward  of  $1,551.  The  Company's  ability  to  utilize  its tax credit
carry-forwards in future years will be subject to an annual limitation  pursuant
to the "Change in  Ownership  Rules" under  Section 382 of the Internal  Revenue
Code of 1986, as amended. However, any annual limitation is not expected to have
a material  adverse  effect on the  Company's  ability to utilize its tax credit
carry-forwards.

     The Company  currently plans to expend  approximately  $2.0 million for the
expansion  and   development  of  its   manufacturing,   marketing  and  general
administrative  capabilities in connection with the fulfillment of the Company's
marketing program and the anticipated launch of the Company's products currently
under  development.  Additionally,  the Company  utilizes  cash  generated  from
operating activities to meet its capital requirements.

     The  Company  expects its capital  requirements  to increase  over the next
several years as it commences new research and development  efforts,  undertakes
new product development,  increases sales and administration  infrastructure and
embarks on developing in-house  manufacturing  capabilities and facilities.  The
Company's future liquidity and capital funding requirements will depend on
numerous  factors,  including the extent to which the Company's  products  under
development are successfully developed and gain market acceptance, the timing of
regulatory  actions regarding the Company's  potential  products,  the costs and
timing of expansion of sales, marketing and manufacturing activities, facilities
expansion  needs,  procurement  and  enforcement  of  patents  important  to the
Company's business, results of clinical investigations and competition.

     The Company  believes that its available cash and cash from operations will
be  sufficient  to satisfy  its  funding  needs for at least the next 36 months.
Thereafter,  if cash generated from  operations is  insufficient  to satisfy the
Company's working capital and capital expenditure requirements,  the Company may
be required to sell additional  equity or debt  securities or obtain  additional
credit facilities.  There can be no assurance that such financing,  if required,
will be available on satisfactory terms, if at all.

                                       11



<PAGE>


                                     PART II
                                OTHER INFORMATION

Item 1. Legal Proceedings.

     None

Item 2. Changes in Securities

As of September 30, 1997,  the Company issued  6,448,606  shares of common stock
for the the acquisition of the certain patented technologies.

As of September 30, 1997,  the Company sold  2,000,000  pursuant to Regulation D
for an aggregate consideration of $2,000 or $.001 per share.

Item 3. Defaults upon Senior Securities

     None.

Item 4. Submission of Matters to a Vote of Security-Holders

     None.


                                       12



<PAGE>


                                   SIGNATURES



     In accordance with the requirements of the Securities Exchange Act of 1934,
the  registrant  has  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.




                                    D-LANZ DEVELOPMENT GROUP, INC.
                                               (Registrant)

                                    By: s/Roger Fidler
                                        ------------------
                                        Roger Fidler,
                                        President and Principal
                                        Executive Officer and
                                        Principal Financial Officer


              Dated: October 29, 1997







                                       13